Want to see JP:3401 full AI Analyst Report?
3401 Stock Chart & Stats
¥1681.00
-¥2.00(-0.12%)
At close: 4:00 PM EDT
¥1681.00
-¥2.00(-0.12%)
Day’s Range― - ―
52-Week Range¥1,202.50 - ¥1,773.00
Previous CloseN/A
Volume0.00
Average Volume (3M)1.23M
Market Cap
¥314.45B
Enterprise Value¥502.72K
Total Cash (Recent Filing)¥104.47B
Total Debt (Recent Filing)¥336.41B
Price to Earnings (P/E)―
Beta0.88
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.05%
Share Statistics
EPS (TTM)-456.37
Shares Outstanding197,953,700
10 Day Avg. Volume898,600
30 Day Avg. Volume1,234,116
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.86
Price to Sales (P/S)0.36
P/FCF Ratio6.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,634.00Price Target Upside-2.80% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)230.2
Revenue Forecast (FY)¥872.60B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained positive operating cash flow (~99B) and large free cash flow (~55B) provide durable internal funding to support operations, capex and dividends even while earnings are negative. This cash resilience lowers short-term refinancing risk and buys time to restore margins.
Diversified Specialty BusinessesA diversified mix of advanced fibers, resins, composites and healthcare services spreads end-market exposure and anchors recurring revenue. Specialty materials and downstream composites create higher-margin opportunities and customer lock-in through technical qualification and long-term OEM relationships.
Track Record Of Prior ProfitabilityHistorical profitable performance and periods of strong margins indicate the business model can generate healthy returns when product mix, pricing or end-market demand normalize. That track record supports management's ability to rebuild margins versus a pure cyclical or structurally weak business.
Bears Say
Deteriorated ProfitabilitySharp swing to sizable losses (≈-10% net margin and negative operating profits) is a lasting earnings quality concern. Persistent negative margins will erode equity, constrain reinvestment, and require sustained cash generation or corrective actions to avoid structural deterioration of competitive capabilities.
Falling Revenue TrendMaterial multi-period revenue decline reduces scale economics and weakens pricing leverage for specialty products. Lower top-line volumes can magnify margin pressure through underabsorbed fixed costs and make it harder to fund R&D or qualifying cycles that sustain long-term customer relationships.
Moderate Leverage And Weakened ReturnsLeverage near 0.9 combined with sharply negative ROE reduces financial flexibility. Continued losses could force higher borrowing costs or asset disposals to restore capital ratios. With only moderate cash-to-debt coverage, deleveraging will depend on sustained cash flow improvement.
Teijin News
3401 FAQ
What was Teijin Limited’s price range in the past 12 months?
Teijin Limited lowest stock price was ¥1202.50 and its highest was ¥1773.00 in the past 12 months.
What is Teijin Limited’s market cap?
Teijin Limited’s market cap is ¥314.45B.
When is Teijin Limited’s upcoming earnings report date?
Teijin Limited’s upcoming earnings report date is Nov 09, 2026 which is in 96 days.
How were Teijin Limited’s earnings last quarter?
Teijin Limited released its earnings results on Aug 04, 2026. The company reported ¥233.81 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Teijin Limited overvalued?
According to Wall Street analysts Teijin Limited’s price is currently Overvalued.
Does Teijin Limited pay dividends?
Teijin Limited pays a Semiannually dividend of ¥25 which represents an annual dividend yield of 3.05%. See more information on Teijin Limited dividends here
What is Teijin Limited’s EPS estimate?
Teijin Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Teijin Limited have?
Teijin Limited has 197,953,700 shares outstanding.
What happened to Teijin Limited’s price movement after its last earnings report?
Teijin Limited reported an EPS of ¥233.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.267%.
Which hedge fund is a major shareholder of Teijin Limited?
Currently, no hedge funds are holding shares in JP:3401
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Teijin Limited
Teijin Limited, a Japanese conglomerate established in Tokyo in 1918, operates on a global scale across diverse sectors. Its core businesses encompass advanced materials, including fibers, films and sheets, and composites, as well as significant operations in healthcare and information technology. The company's materials division provides a comprehensive range of products such as high-performance aramid, carbon, and oxidized PAN fibers, along with various polyethylene materials. This segment also offers specialized items like polytrimethylene telephthalate products, artificial leather materials, polyester nanofibers, and recycled polyester fibers. Its offerings extend to polycarbonate, high-density polyethylene porous, and microporous films and sheets, in addition to PC and polyphenylene sulfide resins, molded parts, and additives. Teijin is also a specialist in composite materials, notably developing lightweight glass and carbon fiber reinforced solutions designed for the automotive industry. In the healthcare sector, Teijin develops pharmaceuticals aimed at treating bone and joint, respiratory, and cardiovascular and metabolic diseases, among others. Furthermore, it supplies an extensive array of medical devices and services, including home oxygen therapy equipment, non-invasive positive pressure ventilation systems, rehabilitation tools, and devices for sleep-disordered breathing. The company also provides a sonic accelerated fracture healing system, community-based integrated care systems, orthopedic implantable devices, and functional food ingredients. Within its IT operations, Teijin offers innovative solutions such as Recopic, a radio-frequency identification (RFID) technology tailored for efficient inventory management. Beyond its product lines, the company is actively involved in engineering solutions, tackling critical global challenges related to environmental pollution, ensuring energy supply stability, and addressing the impact of an aging workforce population.
3401 Company Deck
3401 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted a positive turnaround in net income and an improved operating income forecast. However, significant challenges remain in the Materials and Healthcare segments, with operational issues in the Composites and Aramid businesses. The company faces external pressures from strikes and generic competition but is taking steps to improve profitability.View all JP:3401 earnings summaries3401 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
¥1,634.00
▼(-2.80% Downside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Nisshinbo Holdings
―
Sekisui Chemical Co
―
Noritake Co.,Limited
―
KURABO INDUSTRIES LTD.
―
Aica Kogyo Company, Limited
―




